卡维迪洛尔抑制了由相关的KCNT1突变引起的神经元过敏性
Chang Di1,2, Tong Wu1, Kai Gao3,4,5,6
1State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.
British journal of pharmacology
|October 7, 2024
概括
通过增强激活通道功能,KCNT1 M267T突变导致. 卡维迪洛尔有效地逆转了这些影响,并在小鼠模型中显示出抗发作特性.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- KCNT1突变与有关,治疗选择有限.
- 在KCNT1中M267T突变导致Slack通道中的功能获取.
- 这种突变导致神经元过度兴奋和.
研究的目的:
- 研究KCNT1 M267T突变的病理通道特性.
- 确定突变对神经元刺激性的影响.
- 确定KCNT1突变诱导的的潜在治疗剂.
主要方法:
- 在Xenopus卵细胞和HEK293T细胞中KCNT1的异质表达,用于道属性评估.
- 两电极电压和切割的内外补丁记录.
- 在小鼠的子宫中进行电穿孔,以研究M267T对海马神经元的影响,并评估卡维迪洛在酸诱导的模型中的抗发作活性.
主要成果:
- KCNT1 M267T突变增加了Slack通道开放的概率,导致神经元过度兴奋.
- 卡维迪醇被确定为一种有效的阻断剂,可以逆转突变诱导的功能增益.
- 卡维迪洛尔在的小鼠模型中表现出抗发作作用.
结论:
- 卡维迪洛尔作为一种新型治疗药物,可用于治疗KCNT1相关的.
- 用卡维迪醇向Slack通道功能障碍可能提供一种新的治疗策略.
相关概念视频
Antiepileptic Drugs: Calcium Channel Blockers
338
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
338
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
789
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
789
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
266
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators
341
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341


